RxDoctor Payments Data

Tricia Gilbert, MD

Pulmonary Disease · East Brunswick, NJNPI 1720177090

Payments from drug & device makers

$5,880in general payments, 2019–2025

Across 361 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$836
  • Boehringer Ingelheim$387
  • Mylan Specialty L.p.$329
  • Sanofi$323
  • Harmony Biosciences LLC$270
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,72597%
  • Education$1563%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,880 in reported general payments places this provider in the 70th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$209,616
Medicare patients
658
Services billed
1,660

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter245$223,882
OfevNintedanib Esylate14$196,040
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr149$89,544
Fasenra PenBenralizumab13$83,726
Breztri AerosphereBudesonide/Glycopyr/Formoterol83$63,525
Spiriva RespimatTiotropium Bromide61$50,908
Breo ElliptaFluticasone/Vilanterol85$46,133
NucalaMepolizumab11$35,960
Advair HfaFluticasone Propion/Salmeterol68$32,496
Stiolto RespimatTiotropium Br/Olodaterol Hcl41$24,205
SymbicortBudesonide/Formoterol Fumarate55$21,154
XareltoRivaroxaban13$17,085
Fluticasone-SalmeterolFluticasone Propion/Salmeterol80$12,867
EliquisApixaban18$12,523
Bevespi AerosphereGlycopyrrolate/Formoterol Fum21$10,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala$1,095$395,520490 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$387$271,153116 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$836$94,955159 claims
Johnson & JohnsonXarelto$29$17,08513 claims
PfizerEliquis$29$12,52318 claims
Axsome Therapeutics, Inc.Sunosi$115$9,76112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in East Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →